期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

C3aR和STAT3因子作为免疫复合物肾脏损伤生物标记物的研究 被引量：1

Biomarker study for kidney injury induced by immune complex
原文传递
导出
摘要 目的通过构建免疫复合物肾小球肾炎动物模型,探讨C3aR和STAT3因子作为免疫复合物肾脏损伤的生物标记物辅助诊断的意义。方法 BALB/c小鼠腹腔注射HSA和生理盐水,采用组织病理学、电子显微镜以及免疫组织化学等方法进行研究。结果 HSA组动物表现出免疫复合物肾小球肾炎的变化,并且C3aR、STAT3和p-STAT3因子的表达明显高于阴性对照组。结论 C3aR、STAT3和p-STAT因子可能参与了免疫复合物性肾小球肾炎的发生,有望成为免疫复合物肾脏损伤辅助诊断的生物标记物。 Objective To investigate the mechanism of immune complex glomerulonephritis and discuss the significance of C3aR,STAT3 and p-STAT3 as biomarkers for immune complex glomerulonephritis.Methods HSA（Horse spleen apoferritin） and sodium chloride were intraperitoneally（ip） administrated to BALB/c mice.Pathology examination,electron microscope examination,and immunohistochemistry of C3aR,STAT3 and p-STAT3 were used for pathology evaluation of kidney injury.Results Many changes of immune complex glomerulonephritis were found in HSA group animals.Compared with the control group,the expressions of C3aR,STAT3 and p-STAT3 were increased in kidney of HSA group animals by immunohistochemistry examination.Conclusion C3aR,STAT3 and p-STAT3 should be involved in immune complex glomerulonephritis induced by HAS,and they may become the important biomarkers for the diagnosis of immune complex glomerulonephritis.
作者 林志 张颖丽 吕建军 屈哲 张頔 杨艳伟 李珊珊 李波 孙建宁
机构地区 北京中医药大学 中国药品生物制品检定所
出处 《毒理学杂志》 CAS CSCD 北大核心 2012年第3期165-169,共5页 Journal of Toxicology
关键词 免疫复合物 肾小球肾炎 生物标记物 Immune complex Glomerulonephritis Biomarker
分类号 R991 [医药卫生—毒理学]
  • 相关文献

参考文献17

  • 1Endre ZH, Pickering JW, Walker RJ, et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function[ J]. Kidney Int, 2011, 79 (10) : 1119-1130.
  • 2Bao LH, Hass M, Minto WA, et al. Decay-accelerating factor but not CD59 limits experimental immune-complex glomerulonephritis [ J ]. Lab Invest, 2007, 87 (4) : 357- 364.
  • 3Vaculik C, Ruger BM, Yanagida G, et al. Shift of C3 deposition from localization in the glomerulus into the tubulo-interstitial compartment in the absence of secreted IgM in immune complex glomerulonephritis [ J ]. ClinExpImmunol, 2008, 151 ( 1 ) :146-154.
  • 4Welch RT, Blystone WL. Immune complex glomerulonephritis following bone marrow transplantation in C3 deficient mice[J]. PLoS ONE, 2008, 3(10): 3334.
  • 5Mizuno M, Blanchin S, Gasque P, et al. High levels of complement C3a receptor in the glomeruli in lupus nephritis [J]. Am J kidney Dis, 2007,49(5) :598-606.
  • 6Zhang WX, Chen XM, Shi SZ, et al. Expression and activation of STAT3 in chronic proliferative immune complex glomerulonephritis and the effect of fosinopril[ J ].Nephrol Dial Transplant, 2005. 20(5) : 892-901.
  • 7Leroy V, Fremeaux-Bacchi V, Peuchmaur M, et al. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation [ J ]. Pediatr Nephrol, 2011, 26(3) :419-424.
  • 8Servais A, Fr6meaux-Bacehi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemie syndrome[J]. J Med Genet, 2007,44 (3) :193-199.
  • 9Sheerin NS, Springall T, Abe K et al. Protection and injury : the differing roles of complement in the development of glomerular injury[J]. Eur J Immunol, 2001, 31:1255- 1260.
  • 10Welch TR, Blystone LW. C3 is central to the interstitial complement of experimental immune complex glomerulonephritis [ J ]. Clinlmmunol, 2005, 115 : 80-84.

二级参考文献13

  • 1KEATING S.Biomarkers move to front lineof drug development[J].Drug Discov Devel,2005,8(4):41 -42.
  • 2BOGUSLAVSKY J.Biomarkers as checkpoints[J].Drug Discov Devel,2004,7 (9):26-33.
  • 3LAVIN A.Serum cardiac troponins as biomarkers of drug-induced cardiotoxicity[J].TheToxicologist,2005,84 (S-1):6.
  • 4SEARFOSS GH,RYAN TP,JOLLY RA.The role of transcriptome analysis in pre-clinicaltoxicology[J].Curr Mol Med,2005,5(1):53-64.
  • 5WATERS MD,FOSTEL JM.Toxicogenomics and systems toxicology:aims and prospects[J].Nat RevGenet,2004,5(12):936 -948.
  • 6WETMORE BA,MERRICK BA.Toxicoproteomics:proteomics applied to toxicology andpathology[J].Toxicol Pathol,2004,32(6):619 -642.
  • 7SEARFOSS GH,JORDAN WH,CALLIGARO DO,et al.Adipsin,a biomarker of gastrointestinaltoxicity mediated by a functional-secretase inhibitor[J].J BiolChem,2003,278(46):46107-46116.
  • 8AMACHER DE,ADLER R,HERATH A.Use of proteomic methods to identify serum biomarkersassociated with rat liver toxicity or hypertrophy[J].Clin Chem,2005,51(10):1796-1803.
  • 9BARRIER M,MIRKES PE.Proteomics in developmental toxicology[J].Reprod Toxicol,2005,19(3):291-304.
  • 10GRIFFIN JL,BOLLARD.Metabonomics:its potential as a tool in toxicology for safetyassessment and data integration[J].Curr Drug Metab,2004,5 (5):389-398.

共引文献3

同被引文献6

引证文献1

二级引证文献3

毒理学杂志
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部